Long‐term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapyWilliam J. Sandborn, Brian G. Feagan, Jean‐Frédéric Colombel et al.|Alimentary Pharmacology & Therapeutics|2018Cited by 186
OP010 Long term efficacy and safety of Ustekinumab for Crohn's disease: results from IM-UNITI long-term extension through 2 yearsWilliam J. Sandborn, Brian G. Feagan, P. Rutgeerts et al.|Journal of Crohn s and Colitis|2017Cited by 13
OC-057 A PH3 Randomised, Multicenter, Double-Blind, Placebo (PBO)-Controlled Study of Ustekinumab (UST) Maintenance Therapy in Moderate–Severe Crohn’s Disease (CD) PTS: Results from IM-UNITIWJ Sandborn, B. Feagan, C Gasink et al.|Unknown|2016Cited by 11
LONG-TERM EFFICACY AND SAFETY OF USTEKINUMAB FOR CROHN’S DISEASE: RESULTS FROM IM-UNITI LONG-TERM EXTENSION THROUGH 2 YEARSWilliam J. Sandborn, Bruno Silva, P. Rutgeerts et al.|Arquivos Brasileiros de Cirurgia Digestiva Express|2017Cited by 6
Different Induction Response Criteria Do Not Influence 1-Year Response and Remission Rates of Ustekinumab 90 Mg Q8w in Phase III ProgramDominik Naessens, C Gasink, Jewel Johanns|The American Journal of Gastroenterology|2016Cited by 1